Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

VIRALKUMAR K BHANDERI

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1265518377
CMS profile
741884
Location
TALLAHASSEE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,062.46

63 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,050.54 62
Education $11.92 1

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

VIRALKUMAR K BHANDERI

NPI 1265518377 · CMS profile ID 741884

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

TALLAHASSEE, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1265518377?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
VIRALKUMAR K BHANDERI, NPI 1265518377, CMS profile ID 741884. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1265518377?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). VIRALKUMAR K BHANDERI, NPI 1265518377, CMS profile ID 741884. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1265518377?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
VIRALKUMAR K BHANDERI, NPI 1265518377, CMS profile ID 741884, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–63 of 63 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1265518377?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

63 matching records · $1,062.46 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 63 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–63 of 63.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Daiichi Sankyo Inc. $19.7802/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836261083 CMS
PFIZER INC. $13.0402/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832646549 CMS
Janssen Biotech, Inc. $12.8702/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788050903 CMS
PUMA BIOTECHNOLOGY, INC. $12.9902/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834091973 CMS
AstraZeneca Pharmaceuticals LP $17.3302/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829757313 CMS
Seagen Inc. $14.1202/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832171655 CMS
Coherus Biosciences Inc. $16.0701/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 855095479 CMS
Astellas Pharma US Inc $14.3401/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821261887 CMS
Daiichi Sankyo Inc. $14.7801/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 836251217 CMS
GlaxoSmithKline, LLC. $15.3501/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801659141 CMS
PFIZER INC. $11.3301/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 832553363 CMS
Heron Therapeutics, Inc. $7.2101/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 781450011 CMS
PUMA BIOTECHNOLOGY, INC. $12.0501/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834093663 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 67
PY2020 $309.56 18
PY2021 $1,062.46 63
PY2022 $1,724.83 71
PY2023 $1,848.20 90
PY2024 $1,595.07 57
PY2025 $1,550.83 60

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $299,386.22 525
PY2024 Principal investigator $1,034,772.13 111
PY2023 Principal investigator $936,697.44 176
PY2022 Recipient $4,500.00 1
PY2022 Principal investigator $1,335,427.87 137
PY2021 Principal investigator $1,639,398.18 128
PY2020 Principal investigator $2,123,518.34 86
PY2019 Recipient $3,987.00 9
PY2019 Principal investigator $180,508.39 17

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

525 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640347
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640349
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640351
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640353
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640355
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640357
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640359
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640361
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640363
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640365
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640367
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640369
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640371
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640373
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640375
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640377
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640379
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640381
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640383
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640385
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640387
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640389
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640391
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640393
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640395
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640397
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640399
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640401
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640403
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640405
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640407
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640409
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640411
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640413
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640415
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640417
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640419
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640421
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640423
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640425
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640427
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640429
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640431
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640433
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640435
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640437
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640439
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640441
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640443
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640445
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640447
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640449
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640451
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640453
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640455
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640457
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640459
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640461
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640463
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640465
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640467
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640469
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 12/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640471
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640217
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640219
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640221
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640223
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640225
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640227
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640229
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640231
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640233
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640235
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640237
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640239
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640241
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640243
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640245
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640247
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640249
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640251
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640253
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640255
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640257
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640259
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640261
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640263
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640265
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640267
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640269
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640271
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640273
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640275
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640277
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640279
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640281
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640283
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640285
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640287
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640289
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640291
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640293
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640295
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640297
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640299
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640301
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640303
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640305
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640307
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640309
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640311
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640313
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640315
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640317
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640319
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640321
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640323
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640325
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640327
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640329
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640331
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640333
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640335
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640337
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640339
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640341
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640343
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 11/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640345
Principal investigator 1 PFIZER INC. $300.00 10/21/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228741900
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640099
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640101
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640103
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640105
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640107
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640109
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640111
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640113
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640115
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640117
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640119
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640121
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640123
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640125
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640127
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640129
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640131
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640133
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640135
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640137
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640139
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640141
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640143
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640145
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640147
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640149
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640151
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640153
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640155
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640157
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640159
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640161
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640163
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640165
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640167
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640169
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640171
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640173
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640175
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640177
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640179
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640181
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640183
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640185
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640187
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640189
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640191
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640193
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640195
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640197
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640199
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640201
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640203
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640205
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640207
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640209
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640211
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640213
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 09/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640215
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639979
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639981
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639983
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639985
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639987
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639989
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639991
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639993
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639995
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639997
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639999
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640001
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640003
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640005
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640007
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640009
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640011
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640013
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640015
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640017
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640019
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640021
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640023
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640025
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640027
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640029
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640031
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640033
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640035
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640037
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640039
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640041
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640043
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640045
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640047
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640049
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640051
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640053
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640055
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640057
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640059
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640061
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640063
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640065
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640067
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640069
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640071
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640073
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640075
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640077
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640079
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640081
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640083
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640085
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640087
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640089
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640091
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640093
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640095
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 08/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220640097
Principal investigator 1 ABBVIE INC. $7,007.00 08/14/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202504719
Principal investigator 1 PFIZER INC. $1,000.00 08/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228787070
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639854
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639856
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639858
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639860
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639862
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639864
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639866
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639868
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639870
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639872
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639874
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639876
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639878
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639880
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639882
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639884
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639886
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639888
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639890
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639892
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639894
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639896
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639898
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639900
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639902
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639904
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639906
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639908
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639910
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639912
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639914
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639916
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639918
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639920
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639922
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639924
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639926
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639928
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639930
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639932
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639934
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639937
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639939
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639941
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639943
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639945
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639947
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639949
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639951
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639953
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639955
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639957
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639959
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639961
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639963
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639965
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639967
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639969
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639971
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639973
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639975
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 07/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639977
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639754
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639756
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639758
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639760
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639762
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639764
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639766
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639768
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639770
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639772
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639774
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639776
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639778
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639780
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639782
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639784
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639786
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639788
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639790
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639792
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639794
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639796
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639798
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639800
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639802
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639804
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639806
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639808
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639810
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639812
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639814
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639816
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639818
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639820
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639822
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639824
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639826
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639828
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639830
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639832
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639834
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639836
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639838
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639840
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639842
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639844
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639846
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639848
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639850
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 06/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639852
Principal investigator 1 Amgen Inc. $45,819.00 06/26/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTION LLC
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C No dispute reported 06/30/2026 1246647967
Principal investigator 1 ARRAY BIOPHARMA INC $437.50 06/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228791324
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639626
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639628
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639630
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639632
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639634
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639636
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639638
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639640
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639642
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639644
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639646
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639648
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639650
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639652
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639654
Principal investigator 1 Boehringer Ingelheim International GmbH $975.00 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639656
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639658
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639660
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639662
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639664
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639666
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639668
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639670
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639672
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639674
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639676
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639678
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639680
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639682
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639684
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639686
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639688
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639690
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639692
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639694
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639696
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639698
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639700
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639702
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639704
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639706
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639708
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639710
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639712
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639714
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639716
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639718
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639720
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639722
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639724
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639726
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639728
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639730
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639732
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639734
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639736
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639738
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639740
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639742
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639744
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639746
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639748
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639750
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 05/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639752
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,800.00 05/30/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185554737
Principal investigator 1 ARRAY BIOPHARMA INC $437.50 05/23/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228789958
Principal investigator 1 Mirati Therapeutics, Inc. $1,479.00 05/12/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
A Randomized Phase 3 Study of MRTX849 in Combination With Cetuximab Versus Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation With Disease Progression On or After Standard First-Line Therapy No dispute reported 06/30/2026 1236530685
Principal investigator 1 ABBVIE INC. $3,913.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202480925
Principal investigator 1 ABBVIE INC. $7,462.00 05/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202480927
Principal investigator 1 PFIZER INC. $5,540.00 05/01/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228763745
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 04/30/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS AND RESEARCH INSTITUTE
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185554739
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639570
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639572
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639574
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639576
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639578
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639580
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639582
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639584
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639586
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639588
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639590
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639592
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639594
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639596
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639598
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639600
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639602
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639604
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639606
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639608
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639610
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639612
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639614
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639616
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639618
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639620
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639622
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 04/30/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639624
Principal investigator 1 ABBVIE INC. $381.74 04/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers (PICCOLO) No dispute reported 06/30/2026 1202479591
Principal investigator 1 ARRAY BIOPHARMA INC $546.00 04/25/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228792620
Principal investigator 1 ARRAY BIOPHARMA INC $1,348.75 04/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228791059
Principal investigator 1 ARRAY BIOPHARMA INC $250.00 04/02/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228792681
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639504
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639506
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639508
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639510
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639512
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639514
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639516
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639518
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639520
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639522
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639524
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639526
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639528
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639530
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639532
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639534
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639536
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639538
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639540
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639542
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639544
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639546
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639548
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639550
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639552
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639554
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639556
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639558
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639560
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639562
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639564
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639566
Principal investigator 1 Boehringer Ingelheim International GmbH $24.51 03/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639568
Principal investigator 1 Amgen Inc. $350.00 03/25/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS RESEARCH PANHANDLE
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C No dispute reported 06/30/2026 1246641399
Principal investigator 1 ARRAY BIOPHARMA INC $2,148.75 03/19/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228794376
Principal investigator 1 ABBVIE INC. $2,093.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464069
Principal investigator 1 ABBVIE INC. $2,275.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464072
Principal investigator 1 ABBVIE INC. $3,640.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464077
Principal investigator 1 ABBVIE INC. $3,185.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464085
Principal investigator 1 ABBVIE INC. $8,281.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464090
Principal investigator 1 ABBVIE INC. $2,093.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464095
Principal investigator 1 ABBVIE INC. $5,005.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464099
Principal investigator 1 ABBVIE INC. $819.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464105
Principal investigator 1 ABBVIE INC. $1,729.00 03/18/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202464109
Principal investigator 1 PFIZER INC. $500.00 03/14/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228788958
Principal investigator 1 ABBVIE INC. $2,002.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463120
Principal investigator 1 ABBVIE INC. $7,007.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463132
Principal investigator 1 ABBVIE INC. $11,921.00 03/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
M15-954 - Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome No dispute reported 06/30/2026 1202463135
Principal investigator 1 Novartis Pharmaceuticals Corporation $8,501.65 02/14/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS PAN
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190303207
Principal investigator 1 PFIZER INC. $86,021.28 02/08/2025 Non-covered Recipient Entity
Florida Cancer Specialists PAN SCRI IP
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228761332
Principal investigator 1 PFIZER INC. $6,957.10 02/05/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute LLC
A PHASE 3 RANDOMIZED OPENLABEL MULTICENTER TRIAL OF ARV471 PF07850327 VS FULVESTRANT IN PARTICIPANTS WITH ESTROGEN RECEPTORPOSITIVE HER2NEGATIVE ADVANCED BREAST CANCER WHOSE DISEASE PROGRESSED AFTER PRIOR ENDOCRINE BASED TREATMENT FOR ADVANCED DISEASE VERITAC2 No dispute reported 06/30/2026 1228757100
Principal investigator 1 Amgen Inc. $5,084.38 01/31/2025 Non-covered Recipient Entity
FLORIDA CANCER SPECIALISTS PAN
A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C No dispute reported 06/30/2026 1246641397
Principal investigator 1 Boehringer Ingelheim International GmbH $1,776.25 01/31/2025 Non-covered Recipient Entity
Florida Cancer Specialists And Research Institute Research Data Management Office
An open-label, Phase II, platform trial evaluating safety and efficacy of multiple ezabenlimab anti-PD-1 based combination regimens in PD-(L)1 naive and PD-(L)1 pretreated patient populations with advanced and/or metastatic solid tumours who have had at least one line of systemic therapy No dispute reported 06/30/2026 1220639502
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,000.00 01/22/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185554735
Principal investigator 1 Eli Lilly and Company $30,577.50 01/13/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF FIXED DURATION PIRTOBRUTINIB (LOXO-305) PLUS VENETOCLAX AND RITUXIMAB VERSUS VENETOCLAX AND RITUXIMAB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (BRUIN CLL-322) No dispute reported 06/30/2026 1187888174
Principal investigator 1 Mirati Therapeutics, Inc. $2,959.00 01/06/2025 Non-covered Recipient Entity
Sarah Cannon Research Institute, Llc
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10) No dispute reported 06/30/2026 1236530681
Principal investigator 1 ARRAY BIOPHARMA INC $2,075.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228794557
Principal investigator 1 ARRAY BIOPHARMA INC $125.00 01/03/2025 Non-covered Recipient Entity
SARAH CANNON RESEARCH INSTITUTE LLC
A PHASE 2 OPENLABEL STUDY OF ENCORAFENIB BINIMETINIB IN PATIENTS WITH BRAFV600MUTANT NONSMALL CELL LUNG CANCER No dispute reported 06/30/2026 1228796288